comparemela.com

Latest Breaking News On - Prnewswire astellas pharma inc - Page 1 : comparemela.com

U.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA).

Japan
United-states
Australia
Canada
Tokyo
Shitara
Aichi
United-kingdom
American
America
Moitreyee-chatterjee-kishore
Naoki-okamura

Astellas Announces a Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies

- Focuses on digitizing cell manufacturing processes through robotics technology TOKYO, May 21, 2024 /PRNewswire/ Astellas Pharma Inc. today announced that it signed a memorandum of.

Tokyo
Japan
Naoki-okamura
Astellas-pharma-inc
Prnewswire-astellas-pharma-inc
Safety-of-products-including-pharmaceuticals
Robotic-biology-institute
Medical-device
Astellas-pharma
Cell-therapy-platform-combining-robotics
Medical-device-act
Securing-quality

Astellas Announces A Collaboration With YASKAWA To Create An Innovative Cell Therapy Ecosystem Through The Integration Of Pharmaceutical And Robotics ...

- Focuses on digitizing cell manufacturing processes through robotics technologyTOKYO, May 21, 2024 /PRNewswire/ Astellas Pharma Inc. (

Tokyo
Japan
Naoki-okamura
Robotic-biology-institute
Prnewswire-astellas-pharma-inc
Astellas-pharma-inc
Safety-of-products-including-pharmaceuticals
Medical-device
Astellas-pharma
Cell-therapy-platform-combining-robotics
Medical-device-act
Securing-quality

Astellas Announces a Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies - Astellas Pharma (OTC:ALPMY)

- Focuses on digitizing cell manufacturing processes through robotics technology TOKYO, May 21, 2024 /PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced

Tokyo
Japan
Naoki-okamura
Astellas-pharma-inc
Safety-of-products-including-pharmaceuticals
Robotic-biology-institute
Prnewswire-astellas-pharma-inc
Medical-device
Astellas-pharma
Cell-therapy-platform-combining-robotics
Medical-device-act
Securing-quality

Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the European Commission (EC) has approved a.

Japan
Tokyo
Canada
United-states
Barcelona
Comunidad-autonoma-de-cataluna
Spain
American
America
Antonio-alcaraz
Ahsan-arozullah
European-union

vimarsana © 2020. All Rights Reserved.